Nothing Special   »   [go: up one dir, main page]

Fülöp et al., 2018 - Google Patents

Study on the dissolution improvement of albendazole using reconstitutable dry nanosuspension formulation

Fülöp et al., 2018

View PDF
Document ID
4013313228911737429
Author
Fülöp V
Jakab G
Bozó T
Tóth B
Endrésik D
Balogh E
Kellermayer M
Antal I
Publication year
Publication venue
European Journal of Pharmaceutical Sciences

External Links

Snippet

The aim of the study was to improve the solubility and dissolution rate of the poorly water soluble drug albendazole via surfactant assisted media milling process. Preparation of a nanosuspension and then post-processing with a solidification technique applied to improve …
Continue reading at www.academia.edu (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives

Similar Documents

Publication Publication Date Title
Fülöp et al. Study on the dissolution improvement of albendazole using reconstitutable dry nanosuspension formulation
Wilson et al. Nanoparticle size distribution quantification from transmission electron microscopy (TEM) of ruthenium tetroxide stained polymeric nanoparticles
Li et al. Progress in the development of stabilization strategies for nanocrystal preparations
Pandey et al. Erlotinib loaded chitosan nanoparticles: Formulation, physicochemical characterization and cytotoxic potential
Xu et al. Enhanced dissolution and oral bioavailability of aripiprazole nanosuspensions prepared by nanoprecipitation/homogenization based on acid–base neutralization
Gao et al. Preparation of a chemically stable quercetin formulation using nanosuspension technology
Alshahrani et al. Anticancer efficacy of self-nanoemulsifying drug delivery system of sunitinib malate
Kayaert et al. Is the amorphous fraction of a dried nanosuspension caused by milling or by drying? A case study with Naproxen and Cinnarizine
Romero et al. Industrial concentrates of dermal hesperidin smartCrystals®–production, characterization & long-term stability
Tao et al. Preparation and evaluation of itraconazole dihydrochloride for the solubility and dissolution rate enhancement
Nuchuchua et al. Characterization of drug delivery particles produced by supercritical carbon dioxide technologies
Jassim et al. Formulation and evaluation of clopidogrel tablet incorporating drug nanoparticles
Thakkar et al. Comparative evaluation of electrospraying and lyophilization techniques on solid state properties of Erlotinib nanocrystals: Assessment of In-vitro cytotoxicity
Shid et al. Formulation and evaluation of nanosuspension delivery system for simvastatin
Sepassi et al. Effect of polymer molecular weight on the production of drug nanoparticles
Siahi-Shadbad et al. Development and characterization of solid dispersion for dissolution improvement of furosemide by cogrinding method
Shah et al. Influence of spray drying and dispersing agent on surface and dissolution properties of griseofulvin micro and nanocrystals
Li et al. Formulation of nimodipine nanocrystals for oral administration
Mohamed et al. Optimization, in-vitro release and in-vivo evaluation of gliquidone nanoparticles
Naik et al. Development and evaluation of ibuprofen loaded hydrophilic biocompatible polymeric nanoparticles for the taste masking and solubility enhancement
Aleandri et al. Temperature-induced surface effects on drug nanosuspensions
Hedaya et al. In vitro and in vivo evaluation of ibuprofen nanosuspensions for enhanced oral bioavailability
Imono et al. In-situ dissolution and permeation studies of nanocrystal formulations with second-derivative UV spectroscopy
Vidyadhara Development and characterization of a novel nanosuspension based drug delivery system of valsartan: A poorly soluble drug
Madgulkar et al. Nanoparticulates of fenofibrate for solubility enhancement: ex-vivo evaluation